Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market-Reference-Cited by-同舟云学术

Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market

Published:2021-09-17 Issue:9 Volume:2 Page:e212634
ISSN:2689-0186
Container-title:JAMA Health Forum
language:en
Short-container-title:JAMA Health Forum

Author:

Dean Emma Boswell¹,Bond Amelia M.²

Affiliation:

1. Department of Health Management and Policy, Miami Herbert Business School, University of Miami, Miami, Florida

2. Division of Health Policy and Economics, Department of Population Health Sciences, Weill Cornell Medical College, New York, New York

Publisher

American Medical Association (AMA)

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://jamanetwork.com/journals/jama-health-forum/articlepdf/2784388/dean_2021_ld_210017_1631804863.24876.pdf

Reference6 articles.

1. Biosimilars—curb your enthusiasm.;Yang;JAMA Oncol,2017

2. Baghdadi? R. Health policy brief: biosimilars. Health Affairs. July 21, 2017. Accessed August 14, 2021. https://www.healthaffairs.org/do/10.1377/hpb20170721.487227/full/

3. Mulcahy? AW, Hlavka? JP, Case? SR. Biosimilar cost savings in the United States. RAND Corporation. 2017. Accessed August 14, 2021. https://www.rand.org/pubs/perspectives/PE264.html

4. Aitken? M, Kleinrock? M. Medicine use and spending in the U.S.: a review of 2017 and outlook to 2022. IQVIA Institute. April 19, 2018. Accessed August 15, 2021. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022

5. Factors underlying the growth in Medicare’s spending for physicians’ services. Congressional Budget Office. June 2007. Accessed August 15, 2021. https://www.cbo.gov/sites/default/files/110th-congress-2007-2008/reports/06-06-medicarespending.pdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive Chemotherapy;JCO Oncology Practice;2024-07-24

2. Role of supply chain intermediaries in steering hospital product choice: Group Purchasing Organizations and biosimilars;Health Affairs Scholar;2024-05-15

3. Financial Incentives In Biosimilar Uptake: The Authors Reply;Health Affairs;2023-09-01

4. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program;Health Affairs;2023-05-01

5. Überblick über Maßnahmen zur Förderung des Einsatzes von Biosimilars in europäischen Ländern;Arzneiverordnungs-Report 2023;2023